Base de dados : MEDLINE
Pesquisa : D02.455.326.271.665.202.495.050 [Categoria DeCS]
Referências encontradas : 1002 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 101 ir para página                         

  1 / 1002 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29186241
[Au] Autor:Wang Q; Liu W; Zhang L
[Ad] Endereço:The Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital - Chengdu, China.
[Ti] Título:Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China.
[So] Source:An Bras Dermatol;92(3):319-322, 2017 May-Jun.
[Is] ISSN:1806-4841
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Von Zumbusch type of generalized pustular psoriasis is a rare variant of psoriasis in children. It can occur in patients with or without psoriasis vulgaris. OBJECTIVE: The aim of the study was to discuss the precipitating factors, clinical manifestations, laboratory data and therapy of von Zumbusch type of generalized pustular psoriasis in children from southwestern China and to improve the diagnosis and treatment level. METHODS: A retrospective analysis was conducted for inpatients aged 14 years old or less with von Zumbusch type of generalized pustular psoriasis in our department from 2005 to 2014. RESULTS: A total of 26 patients were included, of whom four (15.38%) had previous history of psoriasis vulgaris and one (3.85%) had previous history of psoriasis arthropathica. Mean onset age was 6.90 years. Gender distribution was equivalent. Incidence of the disease in summer and autumn was higher than that in winter and spring. Nineteen (73.08%) cases were triggered by infection, two (7.69%) cases were caused by sudden discontinuation of systemic use of corticosteroid. Twenty-four (92.31%) cases had concomitant fever. The initial lesion manifested as non-follicular sterile pustules on erythema. Sixteen patients responded well to acitretin, 11 to Tripterygium wilfordii Hook F (TwHF), two to cyclosporine, and one to methotrexate. STUDY LIMITATIONS: This study is a retrospective one and the number of cases is small. CONCLUSION: Von Zumbusch type of generalized pustular psoriasis is a rare disease in children, infection is the most common precipitating factor, acitretin is the first-line therapy, traditional Chinese medicine TwHF also can be used.
[Mh] Termos MeSH primário: Psoríase/diagnóstico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Adolescente
Criança
Pré-Escolar
China
Ciclosporina/uso terapêutico
Feminino
Seres Humanos
Lactente
Masculino
Metotrexato/uso terapêutico
Psoríase/classificação
Psoríase/etiologia
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
83HN0GTJ6D (Cyclosporine); LCH760E9T7 (Acitretin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE


  2 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28476075
[Au] Autor:Jessop S; Whitelaw DA; Grainge MJ; Jayasekera P
[Ad] Endereço:Department of Medicine, University of Cape Town Groote Schuur Hospital, Main Road, 7925 Observatory Cape Town, Cape Town, Western Cape, South Africa.
[Ti] Título:Drugs for discoid lupus erythematosus.
[So] Source:Cochrane Database Syst Rev;5:CD002954, 2017 05 05.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE. OBJECTIVES: To assess the effects of drugs for discoid lupus erythematosus. SEARCH METHODS: We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials. SELECTION CRITERIA: We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender. Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment, surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments. DATA COLLECTION AND ANALYSIS: At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard methods to assess risk of bias, as expected by Cochrane. MAIN RESULTS: Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high quality.'Risk of bias' assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method, and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at low risk in terms of blinding, but three of the five did not describe allocation concealment.The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures).One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low-potency steroid) in 78 people reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n = 78, low-quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two people using fluocinonide (moderate-quality evidence).A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine (RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low-quality evidence). Clearing of erythema in at least 50% of lesions was reported in 10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49, low-quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate-quality evidence).One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17-valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse events.A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one participant, a herpes simplex infection was reactivated (moderate-quality evidence).Topical R-salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate-quality evidence). AUTHORS' CONCLUSIONS: Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate-quality evidence found adverse events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical steroids with other agents.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/uso terapêutico
Lúpus Eritematoso Discoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Acitretina/efeitos adversos
Acitretina/uso terapêutico
Albuterol/uso terapêutico
Inibidores de Calcineurina/uso terapêutico
Fármacos Dermatológicos/efeitos adversos
Fluocinonida/uso terapêutico
Seres Humanos
Hidrocortisona/uso terapêutico
Hidroxicloroquina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Tacrolimo/análogos & derivados
Tacrolimo/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Calcineurin Inhibitors); 0 (Dermatologic Agents); 2W4A77YPAN (Fluocinonide); 4QWG6N8QKH (Hydroxychloroquine); 7KYV510875 (pimecrolimus); LCH760E9T7 (Acitretin); QF8SVZ843E (Albuterol); WI4X0X7BPJ (Hydrocortisone); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD002954.pub3


  3 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28400341
[Au] Autor:Yu C; Fan X; Li Z; Liu X; Wang G
[Ad] Endereço:Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
[Ti] Título:Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
[So] Source:Eur J Dermatol;27(2):150-154, 2017 Apr 01.
[Is] ISSN:1952-4013
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Although acitretin has been widely used for the treatment of psoriasis, additional safer and more effective approaches, including traditional Chinese medicine, are needed. To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multi-centre clinical study was conducted. In total, 108 patients with moderate-to-severe plaque psoriasis were randomly assigned to treatment with "TGP plus acitretin" (group A) or "placebo plus acitretin" (group B) for 12 weeks. After 12 weeks of therapy, the percentage of patients achieving a 50% reduction in Psoriasis Area and Severity Index was 90% in group A and 70.5% in group B (p<0.05). The rate of serum alanine aminotransferase elevation was 6.25% in group A and 20.4% in group B (p<0.05). TGP is conducive to enhancing anti-psoriatic efficacy and reducing liver damage due to acitretin. TGP combined with acitretin is a safe and effective treatment approach for moderate-to-severe plaque psoriasis.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Glucosídeos/uso terapêutico
Ceratolíticos/uso terapêutico
Paeonia/química
Fitoterapia
Extratos Vegetais/uso terapêutico
Psoríase/tratamento farmacológico
[Mh] Termos MeSH secundário: Acitretina/efeitos adversos
Adulto
Alanina Transaminase/sangue
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Glucosídeos/efeitos adversos
Seres Humanos
Ceratolíticos/efeitos adversos
Masculino
Meia-Idade
Extratos Vegetais/efeitos adversos
Raízes de Plantas
Fatores de Proteção
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Glucosides); 0 (Keratolytic Agents); 0 (Plant Extracts); EC 2.6.1.2 (Alanine Transaminase); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1684/ejd.2016.2946


  4 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28329527
[Au] Autor:Joshipura D; Goldminz A; Greb J; Gottlieb A
[Ad] Endereço:Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. djoshipura@tuftsmedicalcenter.org.
[Ti] Título:Acitretin for the treatment of recalcitrant plantar warts.
[So] Source:Dermatol Online J;23(3), 2017 Mar 15.
[Is] ISSN:1087-2108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Plantar warts caused by human papilloma virus (HPV)may be challenging to treat when conventionalmodalities fail. We report a case of severely recalcitrantplantar warts, successfully treated with oral acitretinand topical 40% urea cream.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Dermatoses do Pé/tratamento farmacológico
Ceratolíticos/uso terapêutico
Ureia/uso terapêutico
Verrugas/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Adulto
Doenças do Pé/tratamento farmacológico
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Keratolytic Agents); 8W8T17847W (Urea); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  5 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28328264
[Au] Autor:Croney S
[Ad] Endereço:Clinical Nurse Lead Dermatology, Medway NHS Foundation Trust.
[Ti] Título:Management of patients with psoriasis.
[So] Source:Br J Nurs;26(5):260-262, 2017 Mar 09.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Stacey Croney, Clinical Nurse Lead Dermatology, Medway NHS Foundation Trust, Kent discusses the care of patients with psoriasis, including the latest drug treatments.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Emolientes/uso terapêutico
Imunossupressores/uso terapêutico
Fototerapia
Psoríase/terapia
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Administração Cutânea
Betametasona/uso terapêutico
Calcitriol/análogos & derivados
Calcitriol/uso terapêutico
Ciclosporina/uso terapêutico
Gerenciamento Clínico
Seres Humanos
Ceratolíticos/uso terapêutico
Metotrexato/uso terapêutico
Psoríase/diagnóstico
Psoríase/patologia
Talidomida/análogos & derivados
Talidomida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Dermatologic Agents); 0 (Emollients); 0 (Immunosuppressive Agents); 0 (Keratolytic Agents); 143NQ3779B (calcipotriene); 4Z8R6ORS6L (Thalidomide); 83HN0GTJ6D (Cyclosporine); 9842X06Q6M (Betamethasone); FXC9231JVH (Calcitriol); LCH760E9T7 (Acitretin); UP7QBP99PN (apremilast); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170615
[Lr] Data última revisão:
170615
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.5.260


  6 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28249057
[Au] Autor:Généreux AD; Wetter DA
[Ad] Endereço:Internal Medicine Residency, Abbott-Northwestern Hospital, Minneapolis, MN, USA. Email:andre.genereux@allina.com.
[Ti] Título:Widespread erythematous skin eruption.
[So] Source:J Fam Pract;66(3):181-183, 2017 Mar.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The patient presented with a salmon-colored rash from head to toe. The distinctive clinical presentation and a biopsy pointed to an uncommon diagnosis.
[Mh] Termos MeSH primário: Acitretina/administração & dosagem
Pitiríase Rubra Pilar
Pele/patologia
[Mh] Termos MeSH secundário: Biópsia/métodos
Diagnóstico Diferencial
Feminino
Seres Humanos
Ceratolíticos/administração & dosagem
Meia-Idade
Pitiríase Rubra Pilar/diagnóstico
Pitiríase Rubra Pilar/tratamento farmacológico
Pitiríase Rubra Pilar/fisiopatologia
Resultado do Tratamento
Vitamina A/análogos & derivados
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Keratolytic Agents); 11103-57-4 (Vitamin A); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE


  7 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28194751
[Au] Autor:Lau BW; Lim DZ; Capon F; Barker JN; Choon SE
[Ad] Endereço:School of Medicine and Health Sciences, Monash University, Melbourne, Vic., Australia.
[Ti] Título:Juvenile generalized pustular psoriasis is a chronic recalcitrant disease: an analysis of 27 patients seen in a tertiary hospital in Johor, Malaysia.
[So] Source:Int J Dermatol;56(4):392-399, 2017 Apr.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Limited information exists regarding juvenile generalized pustular psoriasis (GPP). We aim to determine the clinical profile and outcome of Malaysians with juvenile GPP. METHODS: Review of hospital case notes on patients with juvenile GPP. RESULTS: Twenty-seven patients with juvenile GPP were identified. Female to male ratio was 1.4:1. The median age at onset of GPP was 6.5 years. Ten patients had prior psoriasis with a median pre-pustular duration of 2.7 years. Onset of GPP was earlier in patients without prior psoriasis (5.1 years vs. 12.0 years, P = 0.002). Precipitating factors identified included stress, upper respiratory tract infection, systemic steroid use, vaccination, and pregnancy. A positive family history of psoriasis and GPP was present in six and one patient(s), respectively. Twenty-one patients had acute, five annular, and one localized variant of GPP. Arthritis was present in 22.2%. Fever, leukocytosis, and transaminitis were mainly seen in patients with acute GPP at 80.9, 72.2, and 11.1%, respectively. Among 20 patients screened, eight carry IL36RN variants and one has CARD14 mutation. IL36RN-positive patients have more severe disease characterized by early onset, low prevalence of prior plaque psoriasis, high prevalence of systemic inflammation, and need for continuous long-term systemic therapy. Acitretin and cyclosporine were effective in aborting acute GPP in 100% of 16 and 66.7% of six patients treated, respectively. However, relapses were common. Only three of the 17 patients whose initial acute GPP was controlled with systemic agents were successfully weaned off treatment. CONCLUSIONS: Juvenile GPP is a chronic recalcitrant disease. IL36RN-positive patients have more severe disease.
[Mh] Termos MeSH primário: Complicações na Gravidez/etiologia
Psoríase/tratamento farmacológico
Psoríase/etiologia
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Doença Aguda
Adolescente
Adulto
Idade de Início
Proteínas Adaptadoras de Sinalização CARD/genética
Criança
Pré-Escolar
Doença Crônica
Ciclosporina/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
Feminino
Guanilato Ciclase/genética
Seres Humanos
Interleucinas/genética
Ceratolíticos/uso terapêutico
Malásia/epidemiologia
Masculino
Proteínas de Membrana/genética
Gravidez
Psoríase/patologia
Infecções Respiratórias/complicações
Estudos Retrospectivos
Fatores de Risco
Índice de Gravidade de Doença
Esteroides/efeitos adversos
Estresse Psicológico/complicações
Centros de Atenção Terciária
Vacinação/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CARD Signaling Adaptor Proteins); 0 (Dermatologic Agents); 0 (IL36RN protein, human); 0 (Interleukins); 0 (Keratolytic Agents); 0 (Membrane Proteins); 0 (Steroids); 83HN0GTJ6D (Cyclosporine); EC 4.6.1.- (CARD14 protein, human); EC 4.6.1.2 (Guanylate Cyclase); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170215
[St] Status:MEDLINE
[do] DOI:10.1111/ijd.13489


  8 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28181669
[Au] Autor:Kojanova M; Fialova J; Cetkovska P; Gkalpakiotis S; Jircikova J; Dolezal T; Arenberger P; BIOREP study group
[Ad] Endereço:Department of Dermatovenereology, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
[Ti] Título:Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
[So] Source:Int J Dermatol;56(4):428-434, 2017 Apr.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries. METHODS: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST. RESULTS: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%). CONCLUSION: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.
[Mh] Termos MeSH primário: Produtos Biológicos/uso terapêutico
Obesidade/epidemiologia
Psoríase/tratamento farmacológico
Psoríase/epidemiologia
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Adulto
Índice de Massa Corporal
Comorbidade
Doença das Coronárias/epidemiologia
Ciclosporina/uso terapêutico
República Tcheca/epidemiologia
Fármacos Dermatológicos/uso terapêutico
Diabetes Mellitus/epidemiologia
Feminino
Seres Humanos
Hiperlipidemias/epidemiologia
Hipertensão/epidemiologia
Ceratolíticos/uso terapêutico
Masculino
Metotrexato/uso terapêutico
Meia-Idade
Fototerapia
Prevalência
Psoríase/terapia
Qualidade de Vida
Sistema de Registros
Retratamento
Estudos Retrospectivos
Fatores de Risco
Índice de Gravidade de Doença
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Dermatologic Agents); 0 (Keratolytic Agents); 83HN0GTJ6D (Cyclosporine); LCH760E9T7 (Acitretin); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.1111/ijd.13543


  9 / 1002 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28146080
[Au] Autor:Zhou X; He Y; Kuang Y; Li J; Zhang J; Chen M; Chen W; Su J; Zhao S; Liu P; Chen M; Shen M; Chen X; Zhu W; Chen X
[Ad] Endereço:Department of Dermatology, XiangYa Hospital, Central South University, Changsha 410008, China. zhouxingchen117@163.com.
[Ti] Título:Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.
[So] Source:Int J Mol Sci;18(2), 2017 Jan 29.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Psoriasis vulgaris is an immune-mediated inflammatory skin disease. Although acitretin is a widely used synthetic retinoid for moderate to severe psoriasis, little is known about patients' genetics in response to this drug. In this study, 179 patients were enrolled in either the discovery set (13 patients) or replication set (166 patients). The discovery set was sequenced by whole exome sequencing and sequential validation was conducted in the replication set by MassArray assays. Four SNPs (single nucleotide polymorphisms) (rs1105223T>C in , rs11086065A>G in , rs3821414T>C in , rs1802073 T>G in ) were found to be significantly associated with acitretin response in either co-dominant or dominant models via multivariable logistic regression analysis, while rs1105223CC (OR = 4.10, 95% CI = 1.46-11.5, = 0.007) and rs11086065AG/GG (OR = 2.76, 95% CI = 1.42-5.37, = 0.003) were associated with no response to acitretin after 8-week treatment. Meanwhile, ARHGEF3 rs3821414CT/CC (OR = 0.25, 95% CI = 0.10-0.68, = 0.006) and SFRP4 rs1802073GG/GT (OR = 2.40, 95% CI, 1.23-4.70, = 0.011) were associated with a higher response rate. Four new genetic variations with potential influences on the response to acitretin were found in this study which may serve as genetic markers for acitretin in psoriasis patients.
[Mh] Termos MeSH primário: Acitretina/uso terapêutico
Exoma
Sequenciamento de Nucleotídeos em Larga Escala
Ceratolíticos/uso terapêutico
Variantes Farmacogenômicos
Psoríase/tratamento farmacológico
Psoríase/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Alelos
Feminino
Seres Humanos
Masculino
Meia-Idade
Razão de Chances
Polimorfismo de Nucleotídeo Único
Psoríase/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Keratolytic Agents); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171001
[Lr] Data última revisão:
171001
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  10 / 1002 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28063630
[Au] Autor:Wang Y; Cheng R; Lu Z; Guo Y; Yan M; Liang J; Huang P; Li M; Yao Z
[Ad] Endereço:Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
[Ti] Título:Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes.
[So] Source:J Dermatol Sci;85(3):235-240, 2017 Mar.
[Is] ISSN:1873-569X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: IL36RN mutation has been identified as one pathogenesis of generalized pustular psoriasis, but the existence of GPP patients without mutation makes this controversial. OBJECTIVE: Our study aimed at assessing the differences in clinical profiles of children with GPP, with and without IL36RN mutation. METHODS: An ambispective case series study involved review of the records of 66 childhood patients with pediatric-onset GPP and without previous psoriasis vulgaris. RESULTS: c.115+6T>C was the most common mutation in this Chinese population with GPP alone. The age at onset was nearly halved in the homozygotes/compound heterozygotes than in IL36RN-negative patients. Besides a more severe inflammatory progression, three minor signs could prioritize patients with GPP for IL36RN screening (confluent lakes of pus (P=0.002), perianal erosion (P=0.014), and flexural erosion (P=0.007)). More patients with the pathogenic mutation converted to ACH than those without mutation (χ2=4.773, P=0.029). Children with GPP with or without IL36RN mutation responded well to oral low-dose acitretin, but IL36RN-positive cases suffered a much higher half-year recurrence rate after withdrawl of acitretin treatment(χ2=10.370, P=0.001). CONCLUSIONS: Specific clinical features can remind dermatologists of the necessity of sequencing diagnosis. The mild pustular phenotype of those without mutation may imply the possible role of the epigenetic changes of IL36RN, or other IL36-blockers in the pathogenesis. Pediatric patients with GPP alone, both with and without IL36RN mutation responded well to low-dose acitretin.
[Mh] Termos MeSH primário: Interleucinas/genética
Psoríase/genética
Psoríase/patologia
[Mh] Termos MeSH secundário: Acitretina/uso terapêutico
Adolescente
Grupo com Ancestrais do Continente Asiático/genética
Criança
Pré-Escolar
Epigênese Genética
Feminino
Predisposição Genética para Doença
Genótipo
Heterozigoto
Homozigoto
Seres Humanos
Ceratolíticos/uso terapêutico
Masculino
Mutação
Estudos Prospectivos
Psoríase/tratamento farmacológico
Recidiva
Estudos Retrospectivos
Supuração/tratamento farmacológico
Supuração/genética
Supuração/patologia
Suspensão de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (IL36RN protein, human); 0 (Interleukins); 0 (Keratolytic Agents); LCH760E9T7 (Acitretin)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170109
[St] Status:MEDLINE



página 1 de 101 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde